Growth Hormone Peptides Explained

Growth hormone secretagogues, compounds that stimulate the body’s own pituitary gland to produce and release more GH, are the most widely used approach to this problem in functional medicine and longevity practice. Sermorelin, ipamorelin, and CJC-1295 are the three most commonly prescribed. This guide explains what they are, how they differ from each other and from synthetic GH, what the evidence shows, and who they tend to suit.

Key Takeaways

• GH secretagogues stimulate the pituitary to produce its own growth hormone, they do not replace GH directly, and the body’s natural feedback mechanisms remain intact.
• Sermorelin mimics natural GHRH and has the shortest half-life, most physiological, daily injection, gradual effects.
• CJC-1295 is a modified GHRH analogue with a much longer half-life, less frequent injection, more sustained GH elevation.
• Ipamorelin acts on a completely different receptor (ghrelin receptor) to trigger GH pulses, and is notable for its clean side effect profile with no cortisol or prolactin elevation.
• CJC-1295 + ipamorelin is the most common combination, targeting two different GH-stimulating pathways simultaneously for amplified effect.
• All GH secretagogues are prohibited under WADA. They are compoundable with a prescription following the February 2026 FDA reclassification.

Understanding the GH Axis First

To understand what secretagogues do, it helps to understand the hormonal signalling pathway they work within. GH is not released in a steady stream, it is secreted in pulses, primarily during deep slow-wave sleep, in response to a cascade of signals from the hypothalamus and pituitary gland.

The Growth Hormone Axis, How the Cascade Works

1
Hypothalamus
Releases GHRH (Growth Hormone-Releasing Hormone) in pulses, the primary upstream signal. Also releases somatostatin, which inhibits GH release, creating a balance.
Sermorelin and CJC-1295 mimic GHRH at this step
2
Pituitary Gland
Somatotroph cells in the anterior pituitary receive GHRH signals and respond by producing and releasing GH into circulation. Also has ghrelin receptors (GHSR) that independently trigger GH release.
Ipamorelin acts directly on pituitary GHSR receptors at this step
3
Bloodstream, GH Pulses
GH is released in pulses. The amplitude and frequency of these pulses determines the anabolic, lipolytic, and repair signals the body receives. Natural pulsatility is important, continuous GH elevation produces different (and less favourable) effects.
4
Liver, IGF-1 Production
GH acts on the liver to stimulate production of IGF-1 (Insulin-like Growth Factor 1), the primary downstream mediator of GH’s anabolic effects on muscle, bone, and connective tissue.
5
Negative Feedback
Rising IGF-1 and GH levels feed back to the hypothalamus and pituitary to reduce further GHRH release and increase somatostatin, naturally limiting the response. Secretagogues work within this system; exogenous GH bypasses it.

GH Secretagogues vs Exogenous HGH: The Key Difference

The most important conceptual distinction in this space is between GH secretagogues and synthetic human growth hormone (HGH, rhGH). They both elevate GH levels, but they do so in fundamentally different ways with different safety implications.

Exogenous HGH
Mechanism
Replaces GH directly, bypasses the pituitary entirely
Feedback system
Suppresses natural GH production via negative feedback. Pituitary “switches off.”
IGF-1 levels
Often supraphysiological, significantly above natural range
GH pattern
Continuous elevation, loses the natural pulsatile pattern
Risk profile
Acromegaly risk, insulin resistance, joint pain, carpal tunnel, potential tumour promotion at high doses
FDA approval
Yes, for GH deficiency and specific conditions only
GH Secretagogues
Mechanism
Signal the pituitary to produce more of its own GH
Feedback system
Natural feedback remains intact. Body’s own regulation continues to operate.
IGF-1 levels
Often rises above the age-adjusted normal range, no ceiling built in
GH pattern
Maintains pulsatile pattern, enhances amplitude, preserves rhythm
Risk profile
Generally more favourable, feedback ceiling limits overproduction. Side effects mild at appropriate doses.
FDA approval
None for general use. Sermorelin had approval (now withdrawn from market). Compoundable as Category 1.

The feedback loop is real, but it is not a ceiling. Because the body’s own regulatory mechanisms remain active, the hypothalamus and pituitary respond to rising GH and IGF-1 by reducing GHRH production and increasing somatostatin, blunting rather than capping how high GH can go. This built-in ceiling is the primary reason secretagogues are considered lower-risk than synthetic GH for non-deficient patients.^[1]

The Three Main Compounds

Sermorelin

GHRH Analogue, Amino acids 1–29 of native GHRH
Half-life
10–20 minutes, shortest of the three
Administration
Daily subcutaneous injection, typically at night
GH elevation
Modest, pulsatile, most physiologically natural pattern
FDA history
Had FDA approval for paediatric GH deficiency (Geref), withdrawn from market, not for safety reasons

Sermorelin is a synthetic analogue of the first 29 amino acids of GHRH, the minimal sequence needed to bind GHRH receptors and stimulate GH release. Its short half-life means it acts briefly, producing a GH pulse that closely mimics the body’s natural nocturnal GH release when administered at bedtime. Because of this physiological mimicry, sermorelin is often described as the gentlest and most natural GH secretagogue, the preferred option for patients seeking a conservative, long-term approach to supporting age-related GH decline. It is particularly used in anti-aging and wellness medicine for adults with low-normal GH levels, where the goal is restoration rather than optimisation. Results accumulate gradually over weeks to months, a feature that can frustrate patients expecting rapid changes but that reflects the compound’s genuinely physiological action.

CJC-1295

Modified GHRH Analogue, Available with or without DAC modification
Half-life (with DAC)
5.8–8.1 days, covalent albumin modification
Half-life (without DAC)
similar to sermorelin
Administration
1–2x weekly (with DAC) or daily (without DAC)
Human evidence
2006 DAC RCT confirmed dose-dependent GH and IGF-1 rises in healthy adults

CJC-1295 is a modified GHRH analogue engineered to resist degradation far longer than natural GHRH or sermorelin. The DAC (Drug Affinity Complex) modification allows it to bind covalently to serum albumin, extending its half-life to 5.8–8.1 days and enabling once or twice weekly injection rather than daily administration. The version without DAC (Mod GRF 1-29) behaves more like sermorelin, a short pulse with daily dosing needed. When combined with ipamorelin, the no-DAC version is generally preferred because it produces discrete GH pulses that preserve physiological pulsatility, rather than the continuous baseline elevation produced by the DAC form. A 2006 randomised human trial demonstrated that subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults, making it one of the few GH secretagogues with published human pharmacodynamic data.^[2]

Ipamorelin

Ghrelin Receptor Agonist (GHSR), Developed by Novo Nordisk
Receptor
Ghrelin receptor (GHSR), entirely different pathway from GHRH
Cortisol effect
None, even at doses 200x higher than GH-releasing dose
GH elevation
Robust and selective, high amplitude, minimal off-target effects
Key advantage
First GH secretagogue to show GHRH-like selectivity for GH without cortisol/ACTH elevation

Ipamorelin is a pentapeptide developed by Novo Nordisk in the late 1990s as a ghrelin receptor agonist. It acts on the ghrelin receptor (GHSR), a completely separate pathway from the GHRH receptor targeted by sermorelin and CJC-1295. This dual-pathway approach is why ipamorelin and CJC-1295 are almost always used together: they trigger GH release through independent mechanisms, producing synergistic amplification of GH pulses that neither achieves alone. Ipamorelin’s standout characteristic is its remarkable receptor selectivity. Earlier GH secretagogues (GHRP-2, GHRP-6, hexarelin) all caused significant cortisol and ACTH elevation as a side effect of ghrelin receptor activation, which limits the anabolic benefit by simultaneously raising catabolic hormones. Ipamorelin does not. A landmark 1998 study by Raun et al. showed ipamorelin produced robust GH release comparable to GHRP-6, but with no significant ACTH or cortisol response even at doses more than 200 times higher than the GH-releasing threshold.^[3]

Why CJC-1295 + Ipamorelin Is the Most Common Combination

The two-pathway logic is the scientific rationale behind the most commonly used GH secretagogue stack in clinical practice. CJC-1295 activates GHRH receptors, the same receptors that respond to the hypothalamus’s natural GHRH signal. Ipamorelin activates ghrelin receptors, the same receptors that respond to the gut-derived hunger hormone ghrelin. These are independent pathways that both converge on the pituitary somatotroph cells to trigger GH release.

When both pathways are activated simultaneously, the resulting GH pulse is substantially larger than either compound produces alone. Published preclinical data consistently shows 3–8x baseline GH elevation with the combination, compared to 2–5x with individual compounds. This amplification occurs while still preserving the pulsatile pattern of GH release, maintaining physiological rhythm rather than producing the flat, continuous GH elevation associated with exogenous HGH.

The Tortoise and the Hare, Together

A useful way to think about the combination: CJC-1295 (without DAC) primes and sustains the GH-releasing environment over hours. Ipamorelin triggers a sharp, selective GH pulse on top of that primed background. The result is a GH release pattern that has both greater amplitude (the “hare”, ipamorelin’s acute pulse) and greater sustained support (the “tortoise”, CJC-1295’s extended GHRH signal). Together, they produce a more robust and complete GH stimulus than either alone.

What the Evidence Supports

Good Evidence
GH and IGF-1 Elevation
The core mechanism is confirmed in humans. CJC-1295 produced sustained, dose-dependent GH and IGF-1 increases in a 2006 RCT. Ipamorelin’s GH-selective release is well-documented in pharmacological studies. What these compounds do at the hormonal level is well-established.
Moderate Evidence
Sleep Quality Improvement
GH is predominantly released during slow-wave (deep) sleep, and the relationship is bidirectional: GH supports sleep quality, and deep sleep drives GH release. GH secretagogues administered at night, particularly ipamorelin, consistently report improved sleep quality and depth as a primary patient-reported benefit. Human data is observational and clinical, not large RCT.
Moderate Evidence
Body Composition
Elevated GH and IGF-1 promote lean mass preservation and fat mobilisation, particularly visceral fat. These effects are well-established for exogenous GH. For secretagogues, the effects are smaller in magnitude (physiological rather than supraphysiological GH elevation) but the evidence base includes human data showing favourable body composition changes in GH-deficient and aging populations.
Moderate Evidence
Recovery and Tissue Repair
GH and IGF-1 drive muscle protein synthesis and connective tissue repair. The mechanistic rationale for GH secretagogues supporting recovery is strong. Direct RCT evidence specifically for secretagogues in injury recovery is limited, but their value as adjuncts to GLP-1 therapy (for lean mass preservation) and to BPC-157/TB-500 protocols (for anabolic environment support) is clinically coherent.
Limited Evidence
GH Deficiency Treatment
Sermorelin had FDA approval for paediatric GH deficiency. Adult GH deficiency treatment typically uses exogenous GH rather than secretagogues, because the pituitary’s own secretory capacity may be compromised. Secretagogues require a functioning pituitary, they cannot compensate for structural pituitary damage.
Limited Evidence
Direct Tendon / Ligament Repair
A 2025 review in Sports Health found that GH’s direct effects on tendon and ligament cells were not clearly positive in vitro, the indirect anabolic effects may be more relevant than direct tissue action. The recovery benefit is better understood as optimising the hormonal environment than as direct structural repair.

Who GH Secretagogues Tend to Suit

Based on the clinical profile and evidence base, GH secretagogues are most appropriately considered for the following patient profiles:

• Adults over 40 with age-related GH decline, GH secretion falls by approximately 14% per decade after peak in the mid-20s. Secretagogues can partially restore GH pulsatility in this population with a more favourable risk profile than exogenous GH.
• Patients on GLP-1 therapy concerned about lean mass loss, GH secretagogues support muscle protein synthesis and may help preserve lean mass during the caloric deficit produced by GLP-1 medications.
• Adults in active recovery from injury or surgery, as part of a broader recovery protocol alongside BPC-157/TB-500, to optimise the anabolic hormonal environment during the proliferative and remodelling phases.
• Adults with poor sleep quality, particularly those with confirmed low GH and disrupted slow-wave sleep, where the bidirectional GH-sleep relationship makes secretagogue therapy both mechanistically coherent and clinically reported as beneficial.
• Body composition goals with age-related metabolic slowdown, appropriate as an adjunct to lifestyle interventions, not as a substitute for them.

⚠️ Who should approach with caution or not use at all:

• Active cancer, recent cancer history, or strong family history, GH and IGF-1 elevation may support tumour growth
• Uncontrolled type 2 diabetes, GH elevation can worsen insulin resistance; close glycaemic monitoring required
• Severe pituitary damage, secretagogues require a functioning pituitary; they cannot overcome structural pituitary failure
• Competitive athletes under WADA, all GH secretagogues are prohibited under Section S2 as Specified Substances (2-year standard sanction)
• Pregnancy and breastfeeding, no safety data; contraindicated

Regulatory Status

GH Secretagogue Regulatory Status

FDA Status
Sermorelin, ipamorelin, and CJC-1295 are not FDA-approved for any human indication. Research-grade products from online vendors are not pharmaceutically appropriate for human use.
WADA Status
All GH secretagogues including sermorelin, ipamorelin, CJC-1295, GHRP-2, GHRP-6, and MK-677 are prohibited under Section S2 at all times. They are classified as Specified Substances, meaning the standard sanction of 2 years can be reduced if the athlete demonstrates no significant fault and no intent to enhance performance, but the burden of proof is high.
Side effects
Generally mild: water retention, mild joint stiffness, increased appetite (particularly with ghrelin-pathway compounds like ipamorelin), and injection-site reactions. CJC-1295 with DAC can cause transient flushing. These typically resolve with dose adjustment. Long-term safety data in humans is limited.

Interested in whether GH peptides are appropriate for your goals?

Our free quiz helps you think through your situation before speaking with a clinician.